Genomic medicine company Chroma Medicine Inc announced on Thursday the appointment of Melissa J Moore, PhD to its board of directors.
Dr Moore is currently a board director and Scientific Advisory Board member for multiple biotechnology companies. She previously served as chief scientific officer, Platform Research, at Moderna Inc (NASDAQ:MRNA).
Dr Moore co-founded the RNA Therapeutics Institute at the University of Massachusetts Medical School and was a professor of Biochemistry & Molecular Pharmacology, Eleanor Eustis Farrington Chair in Cancer Research, and a long-time Investigator at the Howard Hughes Medical Institute.
Catherine Stehman-Breen, M.D., Chroma CEO, said: "Melissa brings decades of experience directing RNA research and drug development at leading pharma companies and in academia. Her deep knowledge will benefit us as we advance our platform of highly potent and durable epigenetic editors to patients, enabling a new class of genomic medicines."
IgGenix presents IGNX001 data at 2024 ASCIA
Biosergen completes first successful BSG005 treatment in invasive fungal trial
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
EydisBio receives USD2.6m SBIR grant from NIH's National Heart, Lung, and Blood Institute
Oncosure introduces Rapid Cancer Screening Test
Bayer and NextRNA collaborate on LncRNA-targeting therapeutics
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial